Do you want to read an article? Please log in or register.
Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON-HF
Heart Failure
Related content
Heart Failure
In-Hospital or Out-of-Hospital Initiation of Sacubitril/Valsartan Versus Valsartan in Patients With Mildly Reduced or Preserved Ejection Fraction After A Worsening Heart Failure Event: The PARAGLIDE-HF Trial
J Am Heart Assoc
Nouhravesh N, Cyr D, Hernandez AF, Morrow DA, Velazquez EJ, Ward J, Sarwat S, Sharma K, Williamson K, Starling RC, Lepage S, Zieroth S, Solomon SD, Mentz RJ
doi: 10.1161/JAHA.124.037899
Heart FailureFurther Publications
Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Proteomic Substudy
J Am Heart Assoc
Patel-Murray NL, Zhang L, Claggett BL, Xu D, Serrano-Fernandez P, Healey M, Wandel S, Chen CW, Jacob J, Xu H, Turner GM, Chutkow W, Yates DP, O'Donnell CJ, Prescott MF, Lefkowitz M, Gimpelewicz CR, Beste MT, Zhao F, Gou L, Desai AS, Jhund PS, Packer M, Pfeffer MA, Redfield MM, Rouleau JL, Zannad F, Zile MR, McMurray JJV, Mendelson MM, Solomon SD, Cunningham JW
doi: 10.1161/JAHA.123.033544
Heart Failure
Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial
Eur Heart J
Peikert A, Vaduganathan M, Claggett BL, Kulac IJ, Litwin S, Zile M, Desai AS, Jhund PS, Butt JH, Lam CSP, Martinez F, Van Veldhuisen DJ, Zannad F, Rouleau J, Lefkowitz M, McMurray JJV, Solomon SD, Packer M
doi: 10.1093/eurheartj/ehaf057
Heart Failure
Cause-specific death in heart failure across the ejection fraction spectrum: A comprehensive assessment of over 100 000 patients in the Swedish Heart Failure Registry
Eur J Heart Fail
Settergren C, Benson L, Shahim A, Dahlström U, Thorvaldsen T, Savarese G, Lund LH, Shahim B
doi: 10.1002/ejhf.3230
COMMENTED
Heart Failure
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA(1c) levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
★ 2
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Lancet Diabetes Endocrinol
Davies MJ, van der Meer P, Verma S, Patel S, Chinnakondepalli KM, Borlaug BA, Butler J, Kitzman DW, Shah SJ, Harring S, Salsali A, Rasmussen S, von Lewinski D, Abhayaratna W, Petrie MC, Kosiborod MN, STEP-HFpEF Trials Committees and Investigators
doi: 10.1016/S2213-8587(24)00304-8
Heart FailureFurther Publications
Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: The REDUCE LAP-HF II Randomized Clinical Trial
JAMA Cardiol
Patel RB, Silvestry FE, Komtebedde J, Solomon SD, Hasenfuß G, Litwin SE, Borlaug BA, Price MJ, Kawash R, Hummel SL, Cutlip DE, Leon MB, van Veldhuisen DJ, Rieth AJ, McKenzie S, Bugger H, Mazurek JA, Kapadia SR, Vanderheyden M, Ky B, Shah SJ
doi: 10.1001/jamacardio.2024.0520
Heart Failure
Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure
J Am Coll Cardiol
Chatur S, Neuen BL, Claggett BL, Beldhuis IE, Mc Causland FR, Desai AS, Rouleau JL, Zile MR, Lefkowitz MP, Packer M, McMurray JJ, Solomon SD, Vaduganathan M
doi: 10.1016/j.jacc.2024.03.392
Heart Failure
Heart failure in Europe: Guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction - the ESC EORP Heart Failure III Registry
Eur J Heart Fail
Lund LH, Crespo-Leiro MG, Laroche C, Zaliaduonyte D, Saad AM, Fonseca C, Čelutkienė J, Zdravkovic M, Bielecka-Dabrowa AM, Agostoni P, Xuereb RG, Neronova KV, Lelonek M, Cavusoglu Y, Gellen B, Abdelhamid M, Hammoudi N, Anker SD, Chioncel O, Filippatos G, Lainscak M, McDonagh TA, Mebazaa A, Piepoli M, Ruschitzka F, Seferović PM, Savarese G, Metra M, Rosano GMC, Maggioni AP, ESC EORP HF III National Leaders and Investigators
doi: 10.1002/ejhf.3445
Heart, Artery and Coronary DiseasesHeart Failure
Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA-HF and DELIVER
Eur J Heart Fail
Abdin A, Kondo T, Böhm M, Jhund PS, Claggett BL, Vaduganathan M, Hernandez AF, Lam CSP, Inzucchi SE, Martinez FA, de Boer RA, Desai AS, Køber L, Sabatine MS, Petersson M, Bachus E, Solomon SD, McMurray JJV, on behalf of the DAPA‐HF and DELIVER Committees and Investigators
doi: 10.1002/ejhf.3350